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ABSTRACT Acute respiratory distress syndrome (ARDS) is immune-driven patholo-
gies that are observed in severe cases of severe acute respiratory syndrome corona-
virus (SARS-CoV) infection. SARS-CoV emerged in 2002 to 2003 and led to a global 
outbreak of SARS. As with the outcome of human infection, intranasal infection of 
C57BL/6J mice with mouse-adapted SARS-CoV results in high-titer virus replication 
within the lung, induction of inflammatory cytokines and chemokines, and immune 
cell infiltration within the lung. Using this model, we investigated the role of the 
complement system during SARS-CoV infection. We observed activation of the com-
plement cascade in the lung as early as day 1 following SARS-CoV infection. To test 
whether this activation contributed to protective or pathologic outcomes, we uti-
lized mice deficient in C3 (C3–/–), the central component of the complement system. 
Relative to C57BL/6J control mice, SARS-CoV-infected C3–/– mice exhibited signifi-
cantly less weight loss and less respiratory dysfunction despite equivalent viral 
loads in the lung. Significantly fewer neutrophils and inflammatory monocytes 
were present in the lungs of C3–/– mice than in C56BL/6J controls, and subse-
quent studies revealed reduced lung pathology and lower cytokine and chemo-
kine levels in both the lungs and the sera of C3–/– mice than in controls. These 
studies identify the complement system as an important host mediator of SARS-
CoV-induced disease and suggest that complement activation regulates a sys-
temic proinflammatory response to SARS-CoV infection. Furthermore, these data 
suggest that SARS-CoV-mediated disease is largely immune driven and that in-
hibiting complement signaling after SARS-CoV infection might function as an ef-
fective immune therapeutic.
IMPORTANCE The complement system is a critical part of host defense to many 
bacterial, viral, and fungal infections. It works alongside pattern recognition recep-
tors to stimulate host defense systems in advance of activation of the adaptive im-
mune response. In this study, we directly test the role of complement in SARS-CoV 
pathogenesis using a mouse model and show that respiratory disease is signifi-
cantly reduced in the absence of complement even though viral load is un-
changed. Complement-deficient mice have reduced neutrophilia in their lungs 
and reduced systemic inflammation, consistent with the observation that SARS-
CoV pathogenesis is an immune-driven disease. These data suggest that inhibi-
tion of complement signaling might be an effective treatment option following 
coronavirus infection.
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Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and2003 from coronaviruses circulating in animal markets in China (1). Emergence of
this novel virus led to a global outbreak of respiratory disease, with over 8,000 human 
cases and 10% mortality (2, 3). In 2012, a new, related zoonotic coronavirus was 
identified in the Middle East, designated Middle East respiratory syndrome coronavirus 
(MERS-CoV), causing severe respiratory disease with greater than 35% mortality (www 
.who.int/emergencies/mers-cov/en) (4). Both SARS-CoV and MERS-CoV cause a range of 
disease from asymptomatic cases to severe acute respiratory distress syndrome (ARDS) 
and respiratory failure (5). Notably, metagenomics and synthetic virus recovery strate-
gies have since revealed the existence of large pools of preepidemic SARS-like bat 
coronaviruses which replicate in primary human airway epithelial cells. These viruses 
are poised for emergence because they both efficiently use human ACE2 entry recep-
tors and resist existing vaccines and immunotherapeutics (6, 7). Due to the ongoing 
threat and continued emergence of new, highly pathogenic coronaviruses from animal 
reservoirs, a thorough understanding of the host-virus interactions that drive SARS-CoV 
pathogenesis will aid the public health response to current and future coronavirus 
outbreaks (8).
The importance of complement in SARS-CoV pathogenesis is controversial. Previous 
studies have investigated the role of known polymorphisms in the mannose-binding 
lectin (MBL) and MBL-associated serine protese-2 (MASP2) genes in SARS-CoV infection 
outcome following the 2003 outbreak but with conflicting results. One retrospective 
analysis showed that people with low or deficient serum MBL levels were more likely 
to become infected with SARS-CoV (9) than those with high MBL levels, suggesting that 
MBL and complement activation play a role in protecting the host from infection. 
However, a second study found no association between MBL haplotype and SARS-CoV 
infection status (10). Additionally, it was shown MBL can bind to the SARS-CoV Spike 
protein in vitro by some groups (11) but not by others (12). Examination of the role of 
the downstream complement gene MASP2 found no association between genotype 
and SARS susceptibility (13). Together, the results leave a general uncertainty about the 
role of complement in response to SARS-CoV infection.
Despite the existing body of literature, the role of complement in SARS-CoV patho-
genesis has never been directly assessed in vivo. The complement system is an ancient 
arm of the innate immune response comprised of multiple proteins whose reactive 
cascade of cleavage products can coordinate the inflammatory response at the sites of 
infection and can be directly antimicrobial. Consisting of more than 30 soluble and cell 
surface-associated proteins, complement is a major component of innate immunity 
that functions to recognize and eliminate invading pathogens (14). Activation of the 
complement system occurs through multiple mechanisms that include three well-
described pathways, the classical, lectin, and alternative complement activation path-
ways (15), and results in proteolytic processing of various components of the comple-
ment system, including C3, C4, and C5. Proteolytic processing of C3 generates an array 
of cleavage products that are involved in amplification of complement activity through 
formation of C3 and C5 convertases, opsonization of pathogens, and attraction and 
activation of leukocytes of both the innate and adaptive arms of the immune response. 
Several studies, including a recent study showing that complement blockade results in 
reduced disease in a MERS-CoV human DPP4 transgenic (hDPP4-Tg) mouse model (16), 
have elucidated protective and pathogenic roles for the complement system following 
infection by a variety of viral pathogens (17). Furthermore, the complement system has 
well-described roles in other pulmonary diseases (18), especially after influenza virus 
and respiratory syncytial virus infection (19–21).
In this study, we assessed the role of the complement system in the pathogenesis 
of SARS-CoV infection. Building from a systems biology analysis that suggested that 
complement was modulated during SARS-CoV infection, we confirmed that comple-
ment was activated upon SARS-CoV challenge. Mice deficient in C3 (C3–/–), the central 
protein of the complement signaling pathway, were protected from SARS-CoV-induced 
weight loss and had reduced pathology, improved respiratory function, and lower
FIG 1 Omics characterization of complement pathway expression and activation. (A) Protein abundance at 1, 2, 4, and 7 days postinfection relative to that in
mock-treated samples. Samples were taken from total lung homogenates, and error bars indicate standard errors of the means (SEM). Each point indicates the
mean of results for 5 mice at a given time. (B) C3 protein cleavage is observed in the lung by Western blotting as early as 24 h following SARS-CoV MA15
infection of C57BL/6J mice. Numbers at the left are molecular weights (in thousands).
levels of inflammatory cytokines/chemokines in the lung and periphery. Importantly, 
the kinetics and magnitude of virus replication in C3–/– and wild-type mice were the 
same, showing that complement does not play a role in controlling virus replica-
tion. We observed complement deposition in the lungs of SARS-CoV-infected mice, 
suggesting that complement activation results in immune-mediated damage to the 
lung. Additionally, serum activation indicates that complement-mediated systemic 
inflammation may drive the pathogenic response to SARS-CoV infection. Together, the 
results indicate that complement plays a critical role in SARS-CoV pathogenesis and 
that inhibition of the complement pathway might be an effective therapeutic to 
coronavirus-mediated disease.
RESULTS
Complement is activated in SARS-CoV MA15-infected mice. While work by other 
laboratories has shown that C3-deficient mice are extremely susceptible to both H5N1 
and H1N1 influenza virus infection (22), the role of complement in SARS-CoV infection 
has not yet been evaluated in vivo. Using a systems biology-based approach, we 
identified the complement pathway as a high-priority target for control of SARS-CoV 
MA15 (the mouse-adapted SARS-CoV) pathogenesis based on weighted gene correla-
tion network analysis (WGCNA) of RNA transcripts in the lungs of mice infected with a 
lethal versus a sublethal dose of SARS-CoV MA15 (23). Because the complement 
signaling cascade is activated through proteolytic cleavage events, we also assessed 
lung proteomics samples for complement protein abundance. C4b, CfB, and C3 all had 
significantly higher abundances in the lungs of mice infected with a lethal dose of 
SARS-CoV MA15 than in those of mice infected with a sublethal dose (Fig. 1A). 
Complement activation is measured by detection of pathway component cleavage 
products. C3, the master regulator of complement signaling, is cleaved into C3a and 
C3b following creation of C3 convertase. C3 activation products (C3 fragments C3a, 
C3b, iC3b, C3dg, and C3c) were detected by Western blotting in lung tissue of 
SARS-CoV MA15-infected mice, but not in control mice, as early as 1 day postinfection 
(dpi) (Fig. 1B), confirming that SARS-CoV MA15 infection activates the complement 
pathway.
FIG 2 Characterization of C3 knockout mice. (A) Weight loss of SARS-CoV MA15-infected C57BL/6J mice, C3–/– mice, or mock-infected mice were measured over
time. (B) Lung titers of SARS-CoV MA15-infected C57BL/6J or C3–/– mice at 2, 4, and 7 days postinfection. nd, not determined. (A and B) Six to 8 mice were used
through day 4, and 3 to 4 mice were used for days 5 to 7. The respiratory function of SARS-CoV MA15-infected C57BL/6J and C3–/– mice and mock-infected
mice was measured using a Buxco whole-body plethysmography system for Penh, a measure of calculated airway resistance (C), EF50, midbreath expiratory
flow (D), and RPEF, the rate of peak expiratory flow (E). *, P  0.05 between mock-infected mice and a given condition. (C to E) Three mice were used for each
infection group, and two mock-infected mice were used.
Multiple complement pathways contribute to SARS-CoV MA15-induced patho-
genesis. To test the importance of the complement signaling pathway in SARS-CoV 
pathogenesis, we infected C3–/– mice and C57BL/6J controls with SARS-CoV MA15. 
Control mice exhibited approximately 15% transient weight loss, with peak weight loss 
at day 3 postinfection (Fig. 2A). In contrast, the C3–/– mice were significantly protected 
from infection, with no significant weight loss evident at any time point. Surprisingly, 
viral titers in the lung were similar in C3–/– and C57BL/6J controls (Fig. 2B), indicating 
that the lack of disease in C3–/– mice is uncoupled from viral replication efficiency and 
that complement signaling is not necessary for SARS-CoV MA15 clearance from the 
lung. We further measured SARS-CoV MA15-induced disease by assessing respiratory 
function using whole-body plethysmography following infection of C57BL/6J and C3–/–
mice. Enhanced pause (Penh) is a calculated measure of airway resistance that we have 
associated with airway debris following SARS-CoV MA15 infection (24). The 50%
exhalation force (EF50) measures the exhalation force midbreath, which increases as 
breathing becomes more difficult. Finally, the ratio of peak expiratory flow (RPEF) is the 
time to peak expiratory flow and has been associated with wheezing following infec-
tion. All three metrics have been shown to change significantly following SARS-CoV 
MA15 infection, with Penh and EF50 increasing following infection and RPEF decreas-
ing. Combined, these measurements show that SARS-CoV MA15-infected animals have 
altered exhalation patterns in their breathing. C3–/– mice exhibit a decreased change in 
Penh and EF50 levels following SARS-CoV MA15 infection relative to those of infected 
C57BL/6J control mice; however, RPEF values were similar between infection conditions 
(Fig. 2C to E). Together, these data indicate that despite the lack of weight loss in C3–/–
mice, the absence of the complement pathway did not alter host control of viral
FIG 3 Histological analysis of C57BL/6J and C3/ lungs at 2 and 4 days postinfection. Representative 
images show 400 magnifications of the large airways (top row), vasculature (middle row), and 
parenchyma (bottom row) of the lung after SARS-CoV MA15 or mock infection of C57BL/6J or C3/ 
mice.
replication or completely abolish respiratory disease following SARS-CoV MA15 infec-
tion.
In order to determine which arm of the complement pathway contributes to 
SARS-CoV MA15 pathogenesis, we infected knockout mice lacking components up-
stream of C3. C4-deficient mice lack the ability to signal through both the classical and 
lectin pathways, while fB-deficient mice lack the ability to signal through the alternative 
pathway. Both mouse strains showed reduced weight loss relative to that of infected 
control mice (see Fig. S1 in the supplemental material) at 3 days postinfection; however, 
neither C4–/– nor fB–/– mice reproduced complete protection from weight loss observed 
in C3–/– controls. Together, the results suggest that multiple arms of the complement 
pathway may be activated and contribute to SARS-CoV-mediated disease through C3 
activation.
Reduced lung pathology in C3–/– mice. Analysis of SARS-CoV MA15-infected lung 
sections showed that the absence of C3 resulted in reduced, but still significant, lung 
pathology. At day 2 postinfection, only minor effects on lung disease were observed 
with airway denudation and debris, the main histopathological phenotypes at this early 
time point; levels of pathology were similar between wild-type and knockout mice 
(Fig. 3; Table S1). C3–/– mice exhibited more airspace inflammation, including eosino-
FIG 4 Complement deposition staining. Complement deposition on lung tissue of C57BL/6J mice (top 
three rows) was assessed by immunohistochemistry. Mice were examined at 2 and 4 dpi and mock 
infected or infected with SARS-CoV MA15. C3–/– mice (bottom row) showed no positive staining.
phils, at 2 dpi than their wild-type controls, although this relationship was reversed later 
in infection. At 4 dpi, C57BL/6J mice displayed pronounced lung pathology, including 
inflammatory cells in the large airway and parenchyma, perivascular cuffing, thickening 
of the interstitial membrane, and low levels of intra-alveolar edema. In contrast, C3–/–
mice showed reduced scores in these areas, consistent with the improved respiratory 
function observed in Fig. 2. Notably, the lung pathology results were not as pro-
nounced as the complete absence of weight loss, suggesting a possible distinction 
between lung disease and overall pathogenesis. We also considered whether the 
decrease in SARS-CoV MA15 pathogenesis in C3–/– mice was due to reduced lung 
damage in the absence of complement pathway signaling. To investigate this possi-
bility, we looked for signs of complement deposition on SARS-CoV MA15 lung tissue. At 
both 2 and 4 dpi, we observed scattered positive staining for complement in the lungs 
of SARS-CoV MA15-infected mice, suggesting that local tissue damage might contrib-
ute to SARS-CoV pathogenesis (Fig. 4). Interestingly, staining was consistently found in 
the parenchyma of the lung and not in the large airways, which are the other main site 
of SARS-CoV MA15 replication. No positive staining was observed in the lungs of C3–/–
mice.
Diminished infiltration of the lungs of a select immune population of infected 
C3–/– mice. In order to identify and quantitate inflammatory cells in the lung, we 
performed flow cytometry at 4 dpi. In parallel with humans exhibiting lung pathology, 
C3–/– mice exhibited significant pulmonary infiltration following SARS-CoV MA15 infec-
tion, but this inflammation was reduced relative to that observed in wild-type mice. 
SARS-CoV MA15-infected C57BL/6J and C3–/– mice had similar total cell counts as well 
as similar percentages of CD45-positive cells in their lungs (data not shown). Consis-
tently with what was observed in human SARS-CoV patients (25), lymphopenia was 
observed in the lungs of both SARS-CoV MA15-infected C57BL/6J and C3–/– mice with 
reduced percentages of B cells (Fig. 5A) and CD4 T cells relative to those in mock-
infected mice following infection. Despite similar overall lymphocyte levels, small but
FIG 5 Inflammatory cells of C57BL/6J mice and C3 knockout mice. Flow cytometric analysis of inflammatory cells present in the lungs of SARS-CoV
MA15-infected or mock-infected C57BL/6J or C3–/– mice at 4 days postinfection. (A) Lymphocytes; (B) myeloid-cell-derived cells (as defined by Misharin et al.
[68]); (C) CD4 T cell activation markers; (D) CD8 T cell activation markers; (E) CD11c– neutrophil activation markers. *, P  0.05. Error bars indicate SEM. Eight
mice were used for all infection groups, and 4 mice were used for all mock-infected groups. Neuts, neutrophils; DC, dendritic cells; MHCIIhi, a high fluorescence
intensity for MHCII staining; MonoMac (inf), inflammatory monocyte-macrophages; Macs, macrophages.
significant differences were observed in levels of T cell activation between infected 
C57BL/6J and C3–/– mice; both CD4 and CD8 T cells in C3–/– mice expressed more Ki-67 
(Fig. 5C and D), an intracellular marker of proliferation, than those in C57BL/6J controls. 
Analysis of myeloid cells in the lung showed that infected C56BL/6J mice had signifi-
cantly higher levels of neutrophils, particularly nonactivated neutrophils, in the lung 
than infected C3–/– mice (Fig. 5B and E). Furthermore, inflammatory monocytes, which 
have previously been associated with increased SARS-CoV MA15 pathogenesis (26), 
were significantly increased in the lungs of wild-type mice but not C3–/– mice (Fig. 5B). 
Finally, we observed significantly more dendritic cells and alveolar macrophages in the 
lungs of SARS-CoV MA15-infected C3–/– mice than in the lungs of infected C57BL/6J 
mice. Together, although C3–/– mice produced a robust immune cell infiltration follow-
ing SARS-CoV infection, they had significant reductions in both inflammatory mono-
cytes and neutrophils relative to controls; both cell types that are associated with 
SARS-CoV pathogenesis (27). Conversely, the presence of activated T cells is associated 
with recovery following infection (28).
In addition to examining inflammatory cells, we evaluated the vascular integrity of 
the lung following SARS-CoV MA15 infection in the presence and absence of C3. We  
observed no differences in the numbers of platelets present in the bronchoalveolar 
lavage (BAL) fluid between C57BL/6J and C3–/– mice at either 2 or 4 days postinfection,
indicating that the absence of C3 does not appear to significantly alter vascular
permeability following infection with SARS-CoV (Fig. S2B).
FIG 6 Cytokine and chemokine abundance levels. Protein abundance in the lung was measured by Bioplex multiplex magnetic bead assay at days 2, 4, and
7 postinfection or in mock-infected mice. MIP-1a, MIP-1b, and monocyte chemoattractant protein (MCP) had similar concentrations in the lungs of C57BL/6J
and C3–/– mice, with peak abundance at 2 days postinfection (A), while G-CSF, IL-6, TNF, and IL-1a expression was highest in C57BL/6J mice at 2 dpi (B). *, P 
0.05; ‡, P  0.1. Error bars indicate SEM, and 3 to 4 mice were tested for each condition.
Cytokine and chemokine levels are significantly decreased in the lungs of C3–/–
mice. To further investigate the inflammatory response to SARS-CoV MA15 infection, 
we measured cytokine and chemokine protein levels in the lung in the presence and 
absence of complement signaling. Multiple protein expression patterns were observed 
in response to infection. MIP1a, MIP1b, and MCP1 are all highly expressed in the lung 
following SARS-CoV MA15 infection of both C57BL/6J and C3–/– mice (Fig. 6A), indicat-
ing that some inflammatory signaling remains intact in the absence of C3. Granulocyte 
colony-stimulating factor (G-CSF), interleukin 6 (IL-6), tumor necrosis factor alpha 
(TNF-), and IL-1a comprised a group of cytokines and chemokines that were more 
highly produced in the lungs of C57BL/6J mice than in C3–/– mice (Fig. 6B), all peaking 
at 2 days postinfection. Notably, these cytokines all have a role in the production, 
recruitment, or differentiation of neutrophils, consistent with the flow cytometry results 
in Fig. 5B. With the exception of RANTES, all inflammatory cytokines and chemokines 
were measured at the highest levels at 2 dpi, indicating that the host immune response 
is triggered quickly following infection with SARS-CoV MA15. Together, these results 
indicate that the absence of complement has an impact on the magnitude of some 
cytokines and chemokines in the lung; however, robust production can occur in either 
the presence or the absence of C3.
SARS-CoV MA15 induces systemic complement activation. The absence of com-
plement signaling resulted in reduced SARS-CoV MA15 pathogenesis, as measured by 
weight loss and a partial reduction of respiratory dysfunction, pathology, immune 
infiltration, and cytokine responses in the lung. We hypothesized that systemic dis-
ease coupled with no change in viral titer might also drive important elements of 
complement-mediated disease. Therefore, we examined sera from wild-type and C3–/–
mice for signs of systemic disease following infection. Western blot analysis showed 
increased levels of C3a-derived fragments in the serum, indicating systemic comple-
ment activation in SARS-CoV MA15-infected mice at 2 dpi (Fig. 7A). Given this result, we 
next examined cytokine and chemokine protein levels for markers of inflammation in 
the sera of SARS-CoV MA15-infected mice. Both MCP-1 and RANTES levels were 
elevated in the serum following infection, regardless of mouse genetic background 
(Fig. 7B). However, numerous cytokines and chemokines, such as IL-5, G-CSF, and KC
FIG 7 Systemic response to SARS-CoV MA15 infection. (A) C3 protein cleavage products are observed by Western blotting in the serum following infection.
Molecular weights are noted at the left (in thousands). rMA15, recombinant MA15. (B) MCP-1 and RANTES levels are similarly elevated following infection in
C57BL/6J and C3–/– mice. (C) G-CSF, KC, and IL-5 all have significantly higher expression in the sera of C57BL/6J mice than in those of C3–/– mice. IL-6 expression
was suggestive of differences. (D) Complement deposition staining in the kidneys of C57BL/6J mice. *, P  0.05; ‡, P  0.06. Error bars indicate SEM, and 3 to
4 mice were used for each condition.
(keratinocyte chemoattractant or CXCL1) were present in significantly higher abun-
dance in the lungs of C57BL/6J mice than in those of C3 knockout mice (Fig. 7C). We 
further examined the possibility that SARS-CoV MA15 infection leads to complement 
deposition outside the lung and found no signs of increased complement staining in 
the kidney (Fig. 7D). Although no complement deposition was seen, the presence of 
both activated complement and inflammatory cytokines in the sera likely contributes to 
a systemic inflammatory response that drives SARS-CoV MA15-mediated weight loss 
following infection.
DISCUSSION
The complement system is a critical part of the host immune response to bacterial 
and viral infection. Originally identified in the 1900s as a heat-sensitive, nonspecific 
complement to the more specific adaptive immune pathways (29), the complement 
system is one way that the innate immune system detects and responds to foreign 
antigens. Because of its potential to damage host tissues, the complement system is 
also tightly regulated through a number of inhibiting proteins that are constitutively 
present in the serum (30). It has previously been shown that complement pathway 
signaling is critical for the protective host immune response to various bacterial
infections (31) as well as some influenza virus and flavivirus infections (22, 32, 33). 
Furthermore, viruses, including herpesviruses, poxviruses, astroviruses, flaviviruses, and 
retroviruses, encode genes to help them evade detection by the complement system 
(17), strong evidence that complement is important in the host antiviral response. The 
host factors that drive protective (22) or pathogenic (34) complement-associated 
responses in viral infection are not well understood. Of particular concern, the anaphy-
latoxins C3a, C4a, and C5a are produced during activation of the complement signaling 
cascade; they have potent proinflammatory properties and can trigger inflammatory 
cell recruitment and neutrophil activation (35). C3a and C5a blockade has been 
proposed as a treatment for acute lung injury (36), and anti-C5a antibody has been 
shown to protect mice from infection with influenza virus (34) and, more recently, 
MERS-CoV (16). Complement recognition is important for the control of paramyxovi-
ruses (37), dengue virus (38), and human T lymphotrophic virus type 1 (HTLV-1) (39), 
and many more viruses have developed means of evading detection by the comple-
ment system (17). In contrast, the data presented here, in conjunction with recent 
findings for Ross River virus (40, 41), influenza virus (34), and well-established autoim-
mune disease (42), demonstrate that complement system activation can also lead to 
exacerbated disease.
Previous reports clearly established the ability of mannose-binding lectin (MBL) to 
bind to the SARS-CoV spike protein (11), dependent on an N-linked glycosylation site; 
however, the role of complement signaling in SARS-CoV pathogenesis was unclear (9, 
10, 13, 43). In this study, we demonstrate that the complement system is activated 
following SARS-CoV MA15 infection (Fig. 1B). However, we did not observe any change 
in viral titer in C3–/– mice (Fig. 2B), indicating an important difference between in vivo 
and in vitro studies and the use of viral pseudoparticles. The absence of complement 
signaling resulted in protection from SARS-CoV MA15-induced weight loss, as shown 
through the use of both C3-deficient mice (Fig. 2A) and activation pathway-specific 
knockout mice (Fig. S1). Respiratory function in C3 knockout mice was improved 
relative to that of control mice, although significant changes in Penh and RPEF were still 
observed, indicating that the elimination of complement signaling did not completely 
remove the effects of SARS-CoV MA15 infection. While analysis of the cellular inflam-
matory response to SARS-CoV MA15 infection revealed modest changes in histopa-
thology and overall inflammatory cell recruitment to the lungs, significant differences 
were observed in pathogenic inflammatory monocyte and neutrophil populations, 
indicating that complement signaling contributes to the broader immune response to 
infection. Immunohistochemical staining revealed that SARS-CoV MA15 infection in-
duced complement deposition in the lung (Fig. 4), similar to that associated with 
pathogenesis in Ross River virus-infected mice (41) and some influenza virus infections 
(34), and it is likely that complement deposition contributes to pulmonary disease and 
inflammatory cell recruitment.
The cytokines and chemokines IL-5, IL-6, KC (CXCL1), and G-CSF have higher 
abundances in the lungs of SARS-CoV MA15-infected wild-type mice than in C3–/– mice 
and are all known to promote neutrophil recruitment. Indeed, significantly more 
neutrophils were observed in the lungs of SARS-CoV MA15-infected C56BL/6J mice 
than in the C3–/– mice (Fig. 5B). Interestingly, while there were fewer neutrophils 
present, the neutrophils found in the lungs of C3–/– mice infected with SARS-CoV MA15 
had significantly more staining of major histocompatibility complex class II (MHC II) and 
the costimulatory molecules CD80 and CD86 (Fig. 5E), indicating a state of activation 
(44). Unpublished data from our laboratory have consistently demonstrated higher 
neutrophil counts in the lungs of mice with severe disease than in those of mice with 
only mild pathogenesis. Additionally, neutrophilia in human SARS-CoV patients was 
associated with a poor outcome of infection (45), and studies of native rat coronavirus 
(46) found both a protective and a pathogenic role for neutrophils following infection. 
Combined, these data demonstrate that the absence of complement provides signifi-
cant improvements in pulmonary disease following SARS-CoV MA15 infection and
suggest that a nonpulmonary cause might also contribute to the lack of weight loss in 
C3–/– mice.
Importantly, our data demonstrate that SARS-CoV MA15 infection activates the 
complement system systematically as well as in the lung (Fig. 7A and 1B). Wild-type 
C57BL/6J mice exhibited an increased abundance of serum cytokines and chemokines 
in response to SARS-CoV MA15 infection (Fig. 7C) in comparison to C3–/– mice. In 
particular, the pyrogenic cytokine IL-6 (47) is present at higher abundance in the lungs 
and sera of C57BL/6J mice than in those of C3–/– mice. IL-1 and TNF- are also more 
abundant in the lungs of C57BL/6J mice, suggesting that wild-type but not C3–/– mice 
develop a fever response to infection that contributes to weight loss and respiratory 
dysfunction phenotypes. While the precise mechanism of complement activation 
following SARS-CoV MA15 infection is still unclear, it is likely through recognition of the 
viral spike glycoprotein and partially mediated by MBL (see Fig. S1 in the supplemental 
material).
The anaphylatoxins produced by the activated complement pathway, C4a, C3a, and 
C5a, have important immunostimulatory roles in vascular permeability and inflamma-
tory cell recruitment (35, 48). C3a and C5a in particular are noted for their roles in 
causing mast cell degranulation, initiating a cytokine storm, promoting vascular per-
meability, and contributing to acute lung injury (36, 49, 50). Furthermore, a C5a 
antibody blockade was recently shown to protect in a model of highly susceptible 
MERS-CoV mice (16). Although there are no reports of mast cell activation following 
SARS-CoV or MERS-CoV infection, activation has been observed both in vitro and in vivo 
following infection with influenza virus (51) and may occur following other severe 
respiratory infections, including coronaviruses. Mast cells release cytokines, including 
IL-6, IL-1, and TNF-, consistent with the inflammatory profile observed following 
SARS-CoV MA15 infection. While this work cannot definitively conclude that the 
complement anaphylatoxins and mast cell activation contribute to SARS-CoV MA15 
pathogenesis, the data are consistent with this possibility, and the concept warrants 
further investigation.
Complement pathway activation is a hallmark of bacterial infection, and genetic 
deficiencies in the complement pathway result in enhanced susceptibility to Strepto-
coccus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae infections (52), 
as well as to sepsis. Interestingly, it has also been shown that SARS-CoV MA15 infection 
stimulates TLR4 (53, 54), which is classically known as the lipopolysaccharide (LPS) 
receptor (55, 56) and important for recognition of many bacterial infections. Combined, 
these data suggest that host recognition of SARS-CoV MA15 infection may activate 
similar pathways recognizing a bacterial infection, leading to immune signaling cas-
cades that cause systemic disease and enhance viral pathogenesis. While systemic 
activation of the complement pathway may be useful during a bacterial infection, it is 
less so during a localized acute viral infection, such as SARS-CoV. Furthermore, com-
plement activation, in conjunction with the presence of neutrophils, is known to cause 
increased vascular permeability, a condition that is also observed following SARS-CoV 
infection (57–59) and was associated with poor outcome. Baseline complement acti-
vation also increases with age (60, 61), consistent with increased SARS-CoV morbidity 
and mortality in aged populations. Finally, it has previously been reported that serum 
C5a levels are predictive of ARDS development (62) and that, in the absence of 
complement, animals are protected from bacterially induced “shock lung” (63), data 
consistent with the pathogenic role that we have found for complement following 
SARS-CoV MA15 infection.
In this work, we demonstrate that SARS-CoV MA15 infection activates the comple-
ment pathway and that complement signaling contributes to disease following infec-
tion. This disease is likely mediated by complement protein deposition in the lung as 
well as systemic complement activation and inflammation. Notably, the absence of C3 
has no impact on viral titer, unlike what has been observed following influenza virus 
infection. Despite these differences, it is notable that MERS-CoV and H5N1 influenza 
virus-induced acute lung injury and pulmonary inflammation are reduced in mice that
are treated with either a C3a receptor (C3aR) antagonist or antibodies to C5a (16, 34).
A similar treatment might be effective in mitigating SARS-CoV MA15-induced disease,
as SARS, MERS, and influenza have common disease manifestations, including devel-
opment of acute lung injury. Given the large array of zoonotic strains poised for
cross-species transmission, broad-based inhibitors of emerging coronavirus infections
are a high priority (64). Pinpointing the precise arms of the complement pathway that
contribute to SARS-CoV will help further identify therapeutic targets while minimizing
unnecessary inhibition of the immune response. This work suggests that investigation
of anticomplement drugs for treatment of coronavirus infections is warranted and
would pair well with direct antiviral therapeutics.
MATERIALS AND METHODS
Viruses and cells. Stocks of recombinant mouse-adapted SARS-CoV (MA15) (65) were propagated 
and their titers were determined in Vero E6 cells and stored as single-use aliquots at 80°C as previously 
described (66). Tissue titers of MA15 were determined by plaque assay on Vero E6 cells as previously 
described (66, 67), with a limit of detection of 100 PFU. All experiments using live virus were performed 
in a class II biological safety cabinet in a certified biosafety level 3 laboratory with negative air pressure 
and redundant exhaust fans; personnel wore personal protective equipment, including Tyvek suits, 
hoods, and powered air-purifying respirators.
Mouse experiments. C57BL/6J (stock number 000664) and C3–/– (stock number 003641) mice were 
purchased from Jackson Laboratories. fB/ mice were generously provided by Charles Jennette (UNC), 
and C4–/– mice were provided by Mark Heise (UNC). All animal husbandry and experiments were 
performed in accordance with all University of North Carolina at Chapel Hill Institutional Animal Care and 
Use Committee guidelines. Age-matched (10- to 11-week-old) female mice were anesthetized with a 
mixture of ketamine-xylazine and intranasally inoculated with 50 l of phosphate-buffered saline (PBS) 
or 105 PFU of SARS-CoV MA15 diluted in PBS. Mice were monitored for disease signs and weighed at 24-h 
intervals.
Microarray and proteomics analysis. Microarray and proteomics analyses were performed on a 
time course and according to a dose-response study published by Gralinski et al. by following the same 
methods (23). The proteomics data (experiment SM001) are publically available through the PNNL 
(http://omics.pnl.gov) Web portal. Briefly the mean intensity (abundance) for each protein was then 
graphed as an average (5 mice for each infection, 3 mice for mock infection) for each group at each time 
point. Missing or absent values were not scored; however, if no value was observed in any of the samples 
at a time point, the sample was registered with a single 0, representing “not detected.”
Histological analysis. At the times indicated in the figures, mice were euthanized using an overdose 
of isoflurane, and lung tissue was fixed in 10% formalin. Tissues were embedded in paraffin, and 5-m 
sections were prepared. To determine the extent of inflammation and tissue pathology, tissues were 
stained with hematoxylin and eosin and scored in a blind manner from 0 (no sign of phenotype) to 3 
(widespread and severe phenotype).
Platelet counts. For bronchoalveolar lavage (BAL), immediately following euthanasia, 1 ml of PBS 
was injected into the lung through the trachea by using a 22-gauge Exel Safelet catheter tip (Fisher). This 
fluid was then drawn back out and used for subsequent analysis. Two hundred fifty microliters of BAL 
fluid was used for absolute counting of gross cell types using an Abaxis VetScan HM5 analyzer.
Complement deposition staining. Lung sections from SARS-CoV MA15-, Ross River virus-, or 
mock-infected mice were stained for the presence of C3 by the Animal Histopathology and Laboratory 
Medicine Core at the University of North Carolina. SARS-CoV MA15 lung samples were tested from 
20-week-old mice at 1, 2, 4, and 7 days after infection with 105 PFU of virus. Staining was performed using 
a goat anti-mouse C3 primary antibody (MP Biomedicals).
Immunoblot analysis. Mice were perfused with PBS, and then lung tissue was dissected and 
homogenized in lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, and 
0.1% sodium dodecyl sulfate [SDS] supplemented with Complete protease inhibitor cocktail [Roche]). 
Total protein concentrations were determined by using the Coomassie Plus assay kit (Pierce). Dilutions 
of serum or 20- to 30-g aliquots of protein were diluted in an equal volume of 2 SDS sample buffer, 
and SDS-polyacrylamide gel electrophoresis was performed. Proteins were transferred onto polyvi-
nylidene fluoride membranes (Bio-Rad). Membranes were blocked in 1 PBS–5% milk– 0.1% Tween 20 
and incubated with goat anti-mouse C3 antibody (1:1,000; Cappel) overnight at 4°C. Membranes were 
washed in PBS– 0.1% Tween 20 and incubated with rabbit anti-goat-horseradish peroxidase (1:10,000; 
Sigma) for 1 h at room temperature. After a washing step, proteins were visualized by enhanced 
chemiluminescence (Amersham) according to the manufacturer’s instructions.
Flow cytometry. Following euthanasia at 4 days postinfection, mice were perfused with 10 ml of PBS 
via cardiac puncture. Lungs were dissected, minced, and incubated for 90 min with vigorous shaking at 
37°C in digestion buffer (RPMI 1640, 10% fetal bovine serum [FBS], 15 mM HEPES, 2.5 mg/ml collagenase 
A [Worthington], 1.7 mg/ml DNase I [Sigma]). Enzymatically digested tissues were passed through a 
70-m cell strainer and pelleted, and red blood cells were lysed using ammonium-chloride-potassium 
(ACK) lysis buffer. Total numbers of viable cells were determined by trypan blue exclusion. Isolated cells 
were stained in fluorescence-activated cell sorting (FACS) staining buffer (1 Hanks balanced salt 
solution [HBSS], 1% FBS) with the following antibodies: CD45-leukocyte common antigen (LCA)-
allophycocyanin (APC) eFlour780 (clone 30-F11; eBioscience), CD3-peridinin chlorophyll protein (PerCP)
Cy5.5 (clone 145-2C11; eBioscience), CD4-BUV737 (clone RMA4-5; BD), CD8-phycoerythrin (PE) (clone
53-6.7; BD), CD19-BV650 (clone 6D5; BioLegend), CD25-BV510 (clone PC61; BD), CD44-BV786 (clone
IM7; BD), CD62L-BUV395 (clone MEL-14; BD), Ki-67–fluorescein isothiocyanate (FITC) (clone SolA15;
eBioscience), CD69-PECF594 (clone H1.2F3; BD), NK1.1-PE Cy7 (clone PK136; eBioscience), PD-1-BV605
(clone J43; BD), CD45-LCA–APC-R700 (clone 30-F11; BD), CD11b-BV785 (clone M1/70; BioLegend),
CD11c-PECF594 (clone HL3; BD), MHC II-APC (clone M5/114.15.2; eBioscience), Ly6G-APC-Fire780 (clone
1A8; BioLegend), Ly6C-BV605 (clone AL-21; BD), SiglecF-BV650 (clone E50-2440; BD), CD80-BUV737 (clone
16-10A1; BD), CD86-BV421 (clone GL1; BD), and CD103-PerCP-eFluor710 (clone 2E7; eBioscience). After
being stained, cells were fixed in 2% paraformaldehyde overnight and then stored in PBS until
acquisition within 24 h. A minimum of 100,000 events were collected using an LSRII cytometer (Becton,
Dickinson), and analysis was completed using FlowJo software version 10 (TreeStar). All samples were
first evaluated through subsequent gates for (i) mononuclear cells, (ii) doublet exclusion, (iii) dead-cell
exclusion based on uptake of a fixable live/dead cell discriminator (Invitrogen), and CD45-LCA expression
before downstream analyses. Reported cell frequencies were normalized to the percentage of total
CD45-LCA events, where appropriate.
Whole-body plethysmography. Respiratory function was measured using whole-body plethysmog-
raphy as described by Menachery et al. (24). Briefly, mice were loaded into individual chambers and
allowed to acclimate for 30 min before a 5-min measurement window. Measurements were recorded
every 2 s for a total of 150 measurements per time point per mouse.
Cytokine and chemokine protein analysis. The small center lung lobe of each mouse was
homogenized in 1 ml of PBS and briefly centrifuged to remove debris. Fifty microliters of homogenate
was used to measure cytokine and chemokine protein abundance using a Bio-Plex Pro mouse cytokine
23-plex assay (Bio-Rad) according to the manufacturer’s instructions.
Statistical analyses. Percent starting body weights, viral titers, and inflammatory cell numbers were
evaluated for statistically significant differences by the Mann-Whitney test or Student’s t test using
GraphPad Prism software.
Accession number(s). The microarray data were previously deposited in the GEO database under
accession number GSE33266 (23).
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